In addition to the classical SLC7A11 inhibitors (e.g., erastin and sorafenib), subsequent drug screening also found that regorafenib can inhibit SLC7A11, thereby enhancing the anticancer activity of PACMA31 in OVCAR-8 (human ovarian cancer cell line) cells in vitro and in vivo. The gene discussed is SLC7A11; the disease is ovarian cancer.